ERRATUM: BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
ERRATUM: BioSenic on its way to find the necessary funds to globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
PRESS RELEASE – INSIDE INFORMATION Biosenic signs term sheet with SPRIM Global Investments (TrialCap fund) for up to USD 8 million debt financing and USD 800,000 equity investment as a first decisive, financing step towards a Phase 3 clinical trial for its ground-breaking auto-immune medication, a first-in-class drug oral arsenic salt. Mont-Saint-Guibert, Belgium, December 6, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious aut